Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
研究发现，诺和诺德公司的「奥塞米康」神奇减肥药物可将痴呆风险降低48%
Novo Nordisk A/S. (NYSE:NVO) has found that its "miracle" weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
礼来（NYSE: NVO）发现其用于糖尿病的“神奇”减重药物Ozempic与显著降低痴呆和其他认知问题的风险相关。
What Happened: A study conducted at the University of Oxford revealed that patients who used Ozempic had a 48% lower risk of dementia compared to those who used an older drug, sitagliptin. The study also showed a lower risk of cognitive deficits in comparison to patients who had taken either sitagliptin or glipizide, another older medicine, reported Bloomberg on Friday.
发生了什么：牛津大学的一项研究表明，使用Ozempic的患者患痴呆的风险降低了48％，而那些使用较旧药物西格列汀的患者则较高。这项研究还显示相比于那些服用西格列汀或另外一种老药物格列吡嗪的患者，认知缺陷的风险也更低，Bloomberg周五报道。
Patients on Ozempic also had a 28% lower risk...
使用Ozempi...
登录免费看全文
登录/注册